ライフサイエンスコーパス: glomerular

1 The glomerular 3D structure should help to understand its fu

2 tive LTbetaR signaling impaired compensatory glomerular adaptation to renal mass reduction, indicatin

3 del had detectable morphologic or functional glomerular alterations.

4 e (LCDD) is a rare disorder characterized by glomerular and peritubular amorphous deposits of a monoc

5 nts with COVID-19 develop a wide spectrum of glomerular and tubular diseases.

6 e biomarkers may be influenced by changes in glomerular and tubular function in varying patterns, whi

7 Glomerular and tubulointerstitial laminin subunit gamma-

8 IHC of differentially-expressed glomerular and tubulointerstitial proteins can be used t

9 ant to indication biopsy was associated with glomerular area in both cohorts (p-values <=0.001).

10 In the CSC, higher glomerular area was associated with higher eGFR (p-value

11 Glomerular area was associated with indices of microvasc

12 Glomerular area was significantly higher in the CSC than

13 istence of a partial chemical map underlying glomerular arrangement in the dOB.

14 The glomerular basement membrane (GBM) is a key component of

15 /HSPG2 that constitute the axial core of the glomerular basement membrane (GBM).

16 us with areas of foot process effacement and glomerular basement membrane thickening and wrinkling.

17 racterized by ultrastructural lesions of the glomerular basement membrane.

18 complexes along the subepithelial region of glomerular basement membrane.

19 thought to act primarily through regulating glomerular blood flow and reducing filtration pressure.

20 unction despite BP fluctuations and protects glomerular capillaries from hypertensive injury.

21 ellular matrix (ECM) replacement of areas of glomerular capillaries in histologic variants of FSGS ar

22 ighly arborized interdigitating cells on the glomerular capillaries with important function for the g

23 SGLT2 inhibitors lower glomerular capillary hypertension and hyperfiltration, t

24 eased renal vasculature, particularly of the glomerular capillary knot, dysregulation of nephrin and

25 Thus the 3D structure of the glomerular capillary network provides useful information

26 ent membrane (GBM) is a key component of the glomerular capillary wall and is essential for kidney fi

27 ting from immune complexes formed within the glomerular capillary wall.

28 of 53 ml/min per 1.73 m(2)), 195 (30%) had a glomerular cause of CKD.

29 ed the development of glomerular lesions and glomerular cell proliferation at day 4.

30 ia, and pathology, including measurements of glomerular cell proliferation, cellular crescents, neutr

31 mined the therapeutic effects of Tris DBA on glomerular cell proliferation, renal inflammation, and i

32 The mechanisms balancing proteostasis in glomerular cells are unknown.

33 n increase of extracellular matrix, altering glomerular cellular composition.

34 mice exhibited significantly lower levels of glomerular ceramide with decreased podocyte injury compa

35 njury in 86%, cholemic nephrosis in 29%, and glomerular changes in 38%.

36 their primary excitatory input from only one glomerular channel defined by inputs from one class of o

37 h cannot be achieved with hepatobiliary- and glomerular-clearable ICG.

38 untreatable kidney disease characterized by glomerular complement deposition.

39 n of classical monocytes was associated with glomerular damage.

40 and calculations from CT cortical volume and glomerular density on biopsy to assess nephron number.

41 hy (IgAN) diagnosis is based on IgA-dominant glomerular deposits and histological scoring is done on

42 dney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy

43 ngly associated with low eGFR, AKI, CKD, and glomerular deterioration, but not with rejection activit

44 ucture that undergoes key transitions during glomerular development.

45 individual mice after chemical induction of glomerular disease (with Doxorubicin or LPS).

46 to kidney podocytes often results in chronic glomerular disease and consecutive nephron malfunction.

47 In a glomerular disease biorepository cohort (n = 128), we me

48 In one of the largest glomerular disease cohorts to study plasminogen, we vali

49 Glomerular disease presenting as proteinuria with or wit

50 asize the need to treat every patient with a glomerular disease with either an angiotensin-converting

51 e potential strategies to treat non-diabetic glomerular disease.

52 s another potential therapeutic strategy for glomerular disease.

53 the pathology of various diseases, including glomerular disease.

54 enrichment of genes implicated in monogenic glomerular diseases in podocytes.

55 n plasmin (ogen) uria and kidney function in glomerular diseases remains unclear.

56 tients had a high proportion of albuminuria, glomerular diseases such as steroid-resistant nephrotic

57 tive extrarenal SLE, inactive SLE, and other glomerular diseases, and correlated with disease clinica

58 For most glomerular diseases, targeted therapies are lacking.

59 ic nephropathy, as well as other nondiabetic glomerular diseases.

60 emolytic uremic syndrome (aHUS), and various glomerular diseases.

61 promotes podocyte injury and proteinuria in glomerular diseases.

62 cytosed by podocytes to induce apoptosis and glomerular dysfunction kidney disease.

63 used proteomics to test the hypothesis that glomerular ECM composition in collapsing FSGS (cFSGS) di

64 Glomerular endothelial cells (GEC) are a crucial compone

65 tablishes the response of immortalized human glomerular endothelial cells (GEnC) to ionizing radiatio

66 esulted in its deposition exclusively in the glomerular endothelial cells and not in the podocytes of

67 Because the number of glomerular endothelial cells expressing the LTbetaR targ

68 Glomerular endothelium and non-classical monocytes overe

69 rlying mechanisms include podocyte (visceral glomerular epithelial cell/GEC) injury.

70 erens junction abundance, more rosettes, and glomerular expansion.

71 Glomerular expression of testican-2 in human kidneys was

72 The analysis and reporting of glomerular features ascertained by electron microscopy a

73 he glomerulus: high levels of glucose in the glomerular filtrate drive increased reabsorption of gluc

74 As the glomerular filtrate passes through the nephron and into

75 to 4 groups based on their listing estimated glomerular filtration (eGFR) as well as based on their e

76 To clarify the relative contributions of glomerular filtration and tubular uptake to urinary prot

77 The glomerular filtration apparatus presents a barrier again

78 Proper function of the glomerular filtration barrier depends heavily on the int

79 capillaries with important function for the glomerular filtration barrier.

80 an and albumin size selectivity across their glomerular filtration barrier.

81 aintaining the integrity and function of the glomerular filtration barrier.

82 tablishing the selective permeability of the glomerular filtration barrier.

83 This approach to visualizing glomerular filtration function will be instrumental for

84 lants with atrial fibrillation and estimated glomerular filtration rate >=15 mL/(min.1.73 m(2)) were

85 inine ratio 30 to 5000 mg/g and an estimated glomerular filtration rate >=25 to <75 mL per min per 1.

86 patients were prescribed a NOAC in estimated glomerular filtration rate >=90, 60 to 90, 45 to 60, 30

87 ; n = 37) and poor renal function (estimated glomerular filtration rate < 30 mL/min or graft loss at

88 Estimated glomerular filtration rate <30 mL/min per 1.73 m(2) was

89 of HF patients with advanced CKD (estimated glomerular filtration rate <30 mL/min per 1.73 m(2)) fro

90 tin (area under the curve [AUC]4.5/AUC5, for glomerular filtration rate <50 mL/min only) administered

91 bserved in 3 populations: baseline estimated glomerular filtration rate <60 mL.min(-1).1.73 m(-2), al

92 ients with HFrEF and moderate CKD (estimated glomerular filtration rate <60-30 mL/min per 1.73 m(2)),

93 osite outcome of GF, mortality, or estimated glomerular filtration rate <= 20mL/min/1.73m.

94 ic kidney disease (CKD, defined as estimated glomerular filtration rate <=60 mL/min) status.

95 , there were no differences in the estimated glomerular filtration rate (57.7 +/- 18.2 vs 56.3 +/- 17

96 D+ vs 92% D-, P = .9), 1-year mean estimated glomerular filtration rate (63 mL/min D+ vs 57 mL/min D-

97 s age (selected in each of the 1000 splits), glomerular filtration rate (794 splits), diabetes (323 s

98 ody mass index, blood pressure, or estimated glomerular filtration rate (all P for interaction >0.20)

99 participants with normal baseline estimated glomerular filtration rate (eGFR >90 mL/minute/1.73 m2).

100 wiss HIV Cohort Study with a first estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 aft

101 hronic kidney disease at baseline (estimated glomerular filtration rate (eGFR) <= 60 mL/min/BSA) (n =

102 Participants with estimated glomerular filtration rate (eGFR) 59 to 30 mL/min/1.73 m

103 all cases, pre- and postope-rative estimated glomerular filtration rate (eGFR) and serum creatinine w

104 of 2 key kidney disease measures, estimated glomerular filtration rate (eGFR) and urinary albumin-to

105 Estimated glomerular filtration rate (eGFR) based on serum creatin

106 ne albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR) based on serum creatin

107 using 23 covariates, stratified by estimated glomerular filtration rate (eGFR) before imaging (>=60 m

108 tal kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline over 3 years.

109 Patients presented with a mean estimated glomerular filtration rate (eGFR) of 13 +/- 11 mL/min/1.

110 grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60

111 dG were positively associated with estimated glomerular filtration rate (eGFR) over time and a log-un

112 cted individuals but the impact on estimated glomerular filtration rate (eGFR) remains unclear.

113 Median estimated glomerular filtration rate (eGFR) was 43.7 ml/min/1.73 m

114 MRI examination were retrieved and estimated glomerular filtration rate (eGFR) was calculated.

115 WHR), body fat (BF) percentage and estimated glomerular filtration rate (eGFR) were identified.

116 additionally adjusted for BMI and estimated glomerular filtration rate (eGFR) were used.

117 We determined baseline estimated glomerular filtration rate (eGFR) with the Chronic Kidne

118 associated with pre- and post-TAVR estimated glomerular filtration rate (eGFR), and assess associatio

119 ding demographics, blood pressure, estimated glomerular filtration rate (eGFR), and proteinuria.

120 hospitalisation for heart failure, estimated glomerular filtration rate (eGFR), body-mass index, and

121 ence of either: >=50% reduction in estimated glomerular filtration rate (eGFR), end-stage renal disea

122 l renal function measures included estimated glomerular filtration rate (eGFR), proteinuria, and bloo

123 graft failure (ACGF) and 12-month estimated glomerular filtration rate (eGFR), respectively.

124 isease (CKD), defined by a reduced estimated glomerular filtration rate (eGFR).

125 ip between plasmin (ogen) uria and estimated glomerular filtration rate (eGFR).

126 romotryptophan had higher baseline estimated glomerular filtration rate (eGFR, p < 0.001).

127 des correlated negatively with the estimated glomerular filtration rate (eGFR, rho = -0.309, p < 0.00

128 versus MAR, within groups with preoperative glomerular filtration rate (GFR) >=60 mL/min/1.73 m; GFR

129 Glomerular filtration rate (GFR) and urinary albumin exc

130 dney function was assessed by measurement of glomerular filtration rate (GFR) and urine albumin excre

131 Glomerular filtration rate (GFR) assessment is a key asp

132 op clinical/protein models to predict future glomerular filtration rate (GFR) deterioration in this p

133 ith allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1

134 Reduction in glomerular filtration rate (GFR) not meeting CKD criteri

135 Kidney size and glomerular filtration rate (GFR) often increase with the

136 Glomerular filtration rate (GFR) was estimated using the

137 atio of renal oxygen availability (RO(2)) to glomerular filtration rate (GFR), a measure of relative

138 allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy

139 nine (SCr)-based calculations for estimating glomerular filtration rate (GFR).

140 th alcohol use disorder (AUD) and comparable Glomerular Filtration Rate (GFR).

141 Primary end point was glomerular filtration rate (GFR).

142 (r = 0.47 vs. r = 0.29; Meng test p = 0.07), glomerular filtration rate (r = -0.52 vs. r = -0.24; Men

143 onic variants were associated with estimated glomerular filtration rate (rs58720902 at AQR, minor all

144 .16; 95% CI, 0.94-1.43; P = 0.16), estimated glomerular filtration rate 1-y posttransplant (B, 0.58;

145 kidney disease (CKD) at baseline (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m(2) o

146 d kidney function (>=2 measures of estimated glomerular filtration rate [eGFR] <90 mL/min/1.73 m2 >=9

147 was performed among patients with estimated glomerular filtration rate above 60 ml/min/1.73 m(2) at

148 have investigated the prevalence of reduced glomerular filtration rate and albuminuria in the Fontan

149 stages of albuminuria, leading to decline in glomerular filtration rate and end-stage kidney disease

150 year 1 with significantly superior estimated glomerular filtration rate and lowest rate of chronic ki

151 Nephrotic mice displayed decreased glomerular filtration rate and urinary potassium excreti

152 project to identify novel loci for estimated glomerular filtration rate and urine albumin-to-creatini

153 tide polymorphisms associated with estimated glomerular filtration rate are located in the SHROOM3 ge

154 ral issues surrounding the donor candidate's glomerular filtration rate assessment.

155 lerosis on delayed graft function, estimated glomerular filtration rate at 1 y, or long-term graft su

156 Glomerular filtration rate at 12 months and rates of bio

157 The median (range) estimated glomerular filtration rate at 2 years posttransplant was

158 The decrease of estimated glomerular filtration rate at 5 years post-biopsy was si

159 significant (HR, 2.26; P = 0.015); even when glomerular filtration rate at month 3 < 30 mL/min/1.73 m

160 Mean estimated glomerular filtration rate at month 36 was comparable be

161 recommended that patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m(2) be

162 An estimated glomerular filtration rate by chronic kidney disease (CK

163 Measurement of glomerular filtration rate by the plasma clearance of an

164 interaction between treatment and estimated glomerular filtration rate categories for any outcome.

165 isclassified patients according to classical glomerular filtration rate categories in approximately h

166 f serum creatinine doubling or 40% estimated glomerular filtration rate decline, kidney failure, or d

167 mong patients with elevated cfDNA, estimated glomerular filtration rate declined by 8.5% (interquarti

168 All known estimated glomerular filtration rate equations displayed high bias

169 aution when using creatinine based estimated glomerular filtration rate equations.

170 cceptable errors when compared with measured glomerular filtration rate in a mixed ICU population, wi

171 -toxicity, may preserve tubular function and glomerular filtration rate in the long term.

172 ort studies and trials indicate that reduced glomerular filtration rate increases the risk of stroke

173 ed for patients who have AKI or an estimated glomerular filtration rate less than 30 mL/min/1.73 m(2)

174 In patients with estimated glomerular filtration rate less than 60 mL/min/1.73 m, t

175 r, had lower lymphocyte counts and estimated glomerular filtration rate levels, and had higher serum

176 Finally, estimated glomerular filtration rate misclassified patients accord

177 dvanced chronic kidney disease (an estimated glomerular filtration rate of <30 ml per minute per 1.73

178 Nine LD had estimated glomerular filtration rate of <30 mL/min/1.73 m versus 4

179 in-creatinine ratio >300 mg/g, and estimated glomerular filtration rate of 30 to <90 mL/min/1.73 m(2)

180 ith a mean age of 62 +/- 13 y old and a mean glomerular filtration rate of 59 +/- 20 mL/min/1.73m.

181 On average, estimated glomerular filtration rate slope improved postconversion

182 The estimated glomerular filtration rate slope postconversion was comp

183 1.0 years, 50.6% were male, median estimated glomerular filtration rate was 42.3 ml/min/1.73 m2, and

184 Mean measured glomerular filtration rate was 74.7 mL/min and 62.4 mL/m

185 the association of pre-angiography estimated glomerular filtration rate with adverse outcomes.

186 IV single dose of iohexol and estimation of glomerular filtration rate with creatinine or cystatin C

187 the association of pre-angiography estimated glomerular filtration rate with the primary outcome.

188 association of the pre-angiography estimated glomerular filtration rate with these outcomes.

189 0 3A5 genotype, pregraft sensitization, mo 3 glomerular filtration rate).

190 D-dimer cutoff levels (> 333 ug/L [estimated glomerular filtration rate, > 60 mL/min/1.73 m], > 1,306

191 el, >=7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1

192 ble within 3 months before biopsy (estimated glomerular filtration rate, 55.3 +/- 18.9 mL/min/1.73 m)

193 ssociated with kidney-related traits such as glomerular filtration rate, albuminuria, hypertension, e

194 Full blood count, glomerular filtration rate, and liver function test were

195 endpoints: delayed graft function, estimated glomerular filtration rate, and occult UOC.

196 etes (PTD), cardiac complications, estimated glomerular filtration rate, and occurrence of delayed gr

197 dy mass index, smoking, education, estimated glomerular filtration rate, and study center.

198 09 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and overall survival a

199 1) -m in their sensitivity to changes in the glomerular filtration rate, glomerular protein leak, tub

200 >=0.3 mg/dL, or >=25% decrease in estimated glomerular filtration rate, or an increase in cystatin C

201 nd poor accuracy when compared with measured glomerular filtration rate, overestimating renal functio

202 peptide), and fibrosis biomarkers; and lower glomerular filtration rate, peak oxygen consumption, 6-m

203 patients without AKI or with high estimated glomerular filtration rate, penKid was associated with h

204 r age, sex, race, body mass index, estimated glomerular filtration rate, previous myocardial infarcti

205 The effect on estimated glomerular filtration rate, serum creatinine level, and

206 -positive rate can be reduced when estimated glomerular filtration rate-adjusted D-dimer cutoff level

207 stics of previously suggested that estimated glomerular filtration rate-adjusted D-dimer cutoff level

208 k to validate previously suggested estimated glomerular filtration rate-adjusted D-dimer cutoff level

209 t lymphoproliferative disease, and estimated glomerular filtration rate.

210 roalbumin-to-creatinine ratio, and estimated glomerular filtration rate.

211 lated to delayed graft function or estimated glomerular filtration rate.

212 eatinine, blood urea nitrogen, and estimated glomerular filtration rate.

213 Among 28 patients with estimated glomerular filtration rates <30 mL/min who received >=5

214 the cutoff for administering prophylaxis to glomerular filtration rates <30ml/min/1.73m(2) and elimi

215 nction remained stable with a mean estimated glomerular filtration rates of 67 +/- 21 and 71 +/- 19 a

216 Additionally, the influence of varying glomerular filtration rates, kidney somatostatin recepto

217 oss racial/ethnic groups and the spectrum of glomerular filtration rates.

218 istent with extreme lactic acidosis, reduced glomerular filtration, and stress.

219 rresponds to a 3.5-fold elevation in albumin glomerular filtration, supporting the use of microalbumi

220 n about kidney health beyond measurements of glomerular function alone.

221 GLT2 inhibitors to slow the deterioration in glomerular function and reduce the risk of ESKD in large

222 To assess glomerular function in the transplanted human pluripoten

223 n) abolishes PT protein reabsorption leaving glomerular function intact.

224 the maintenance of podocyte architecture and glomerular function via Cdc42 and its downstream Yes-ass

225 cator of renal injury, rather a surrogate of glomerular function.

226 useful information with which to understand glomerular function.

227 as been proposed as a sensitive biomarker of glomerular function.Objectives: In this ancillary study

228 ress, lowered serum uric acid level, reduced glomerular hyperfiltration and albuminuria, and suppress

229 Glomerular hyperfiltration resulting from an elevated in

230 h the noncanonical kinase cascades regulates glomerular hypertrophy and matrix protein deposition, wh

231 ic nephropathy, exhibiting less albuminuria, glomerular hypertrophy, podocyte injury, and interstitia

232 SLN mice also showed significantly decreased glomerular IgG, IgM, and C3 deposits.

233 Live glomerular imaging using confocal microscopy monitored i

234 Proteinuria, blood urea nitrogen, and glomerular immune complex deposition were also exacerbat

235 th a UMOD gene mutation (C106F) resulting in glomerular inflammation and complement deposition.

236 determine their respective contributions to glomerular inflammation.

237 nal knockout (cKO) mouse] is protective from glomerular injuries.

238 xpression in podocytes is up-regulated after glomerular injury because its expression levels are high

239 Glomerular injury is a major cause of CKD, which is epid

240 enic rats showed attenuation of proteinuria, glomerular injury, and kidney fibrosis with aging and mi

241 Amiloride was protective against PAN-induced glomerular injury, reducing CD36 scavenger receptor expr

242 show that TrkC is essential for maintaining glomerular integrity.

243 in synthesis and degradation, which reflects glomerular integrity.

244 on of a major degradative pathway, renal and glomerular involvement is rarely reported, suggesting or

245 (AngII) signaling, a therapeutic mainstay of glomerular kidney diseases, is thought to act primarily

246 ites and by activating sensory inputs in the glomerular layer in truncated GCs lacking dendrodendriti

247 use of microalbuminuria screening to detect glomerular leak in diabetes.

248 dicts quantitatively how hyperfiltration and glomerular leak interact to promote albuminuria.

249 nt with sirolimus reduced the development of glomerular lesions and glomerular cell proliferation at

250 Anti-Thy1.1 transgenic mice develop glomerular lesions that mimic collapsing focal segmental

251 ometry and qPCR further analyzed ex vivo the glomerular leukocyte infiltrate during NTN.

252 demonstrate actin dysregulation in vivo and glomerular maldevelopment that is rescued by WT-DAAM2 mR

253 ptor tyrosine kinase expressed abundantly in glomerular mesangial cells.

254 ecimens with crescentic GN had extracellular glomerular myeloperoxidase deposition that correlated si

255 Extracellular glomerular myeloperoxidase deposition, seen in ANCA-asso

256 (LAMC1) expression decreased in AMR, as did glomerular nephrin (NPHS1) and receptor-type tyrosine-ph

257 al unbiased proteomic analysis revealed that glomerular NPY-NPY2R signaling predicted nephrotoxicity,

258 e then examined how this network transformed glomerular patterns of odorant-evoked sensory input (tak

259 methods are discussed, including an ex vivo glomerular permeability assay that enhances the understa

260 l cells (GEC) are a crucial component of the glomerular physiology and their damage contributes to th

261 Glomerular planar surface area and diameter were measure

262 Increased glomerular plasmin (ogen) was found in PAN rats and foca

263 Glomerular podocyte density gradually decreased in podoc

264 eading to a diminution in autophagic flux in glomerular podocytes and renal tubules and markedly incr

265 In the glomerular podocytes, accumulation of GL3 progresses wit

266 rements that provides an overall estimate of glomerular pressure and afferent and efferent resistance

267 of impaired renal autoregulation, enhancing glomerular pressure exposure.

268 ocytic uptake, water reabsorption, SNGFR and glomerular protein filtration affect excretion.

269 o changes in the glomerular filtration rate, glomerular protein leak, tubular protein uptake via endo

270 We therefore analyzed standard markers of glomerular proteinuria (e.g. immunoglobulin G [IgG]), ur

271 phrin correlated strongly with biomarkers of glomerular proteinuria over time.

272 We also applied single-glomerular proteome analysis to tissue from patients wit

273 The glomerular proteomes of SAGN and IgAN showed remarkable

274 Our findings indicate that glomerular response to podocyte depletion in larval zebr

275 ish strain, podocytes were depleted, and the glomerular response was investigated by histological and

276 lar descriptors performed best in predicting glomerular responses using nonlinear Support-Vector Regr

277 ECM differences suggest that glomerular sclerosis in cFSGS differs from that in other

278 ent arterioles) is relatively independent of glomerular size and is present primarily on the vascular

279 This larger main olfactory bulb glomerular size and number of glomeruli indicates that e

280 previous study has addressed association of glomerular size at the time of a for-cause biopsy and cl

281 ents with well-functioning grafts, increased glomerular size correlates with better survival.

282 Glomerular size in renal allografts is impacted by donor

283 Glomerular size is associated with histopathologic featu

284 expansion, tubular dilation and atrophy, and glomerular size variability.

285 ne controlling for sex, age, race/ethnicity, glomerular status, birth weight, premature birth, angiot

286 ormation underlies the maturation of adrenal glomerular structure postnatally.

287 After vascularization, glomerular structures in the organoid displayed dextran

288 Furthermore, TrkC expression was elevated in glomerular tissue of patients with diabetic kidney disea

289 iabetic kidney disease compared with control glomerular tissue.

290 erosis (FSGS) in humans with collapse of the glomerular tuft and marked hyperplasia of the parietal e

291 IHC showed that glomerular tuft staining for cathepsin B, cathepsin C, a

292 cells deposited extracellular matrix on the glomerular tuft which are all hallmarks of FSGS.

293 twork to segment six major renal structures: glomerular tuft, glomerulus including Bowman's capsule,

294 mic clusters for ORNs and mapped 20 to their glomerular types, demonstrating that transcriptomic clus

295 Monocytes recruited to the glomerular vasculature did not undergo transendothelial

296 When stratified by glomerular versus nonglomerular etiology of CKD, effect

297 n neuron (PN) processes likely contribute to glomerular volume increases, as follows: both occur toge

298 hyalinosis to measure nephrosclerosis; mean glomerular volume, cortex volume per glomerulus, and mea

299 Larger glomerular volume, larger cortex per glomerulus, and hig

300 d with decreased podocyte number density per glomerular volume.